- Primary research
- Open Access
The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy
© Xu et al.; licensee Springer 2014
- Received: 25 January 2014
- Accepted: 30 July 2014
- Published: 12 August 2014
Therapeutic options for patients with non-small cell lung cancer (NSCLC) are often restricted to systemic chemotherapy. However, the molecular and cellular processes during chemotherapy of advanced NSCLC patients still remain unclear. Here we investigated the stimulatory activity of plasma in advanced NSCLC patients and its correlation with chemotherapy.
Whole blood samples from advanced NSCLC patients were collected before the first, second, and third cycle of chemotherapy. Plasma was isolated following centrifugation of whole blood. PBMCs were isolated from whole-blood specimens by Ficoll-Hypaque density gradient centrifugation. Immune complexes (ICs) were isolated from NSCLC plasma using the IgG Purification Kit. qRT-PCR was used to detect a broad array of cytokines and chemokines.
The plasma in advanced NSCLC patients was endowed with stimulatory activity and capable of inducing proinflammatory cytokines. Both nucleic acids and immunoglobulin components were required for the stimulatory activity of NSCLC plasma. In consistent, TLR8 and TLR9 conferred the stimulatory activity of plasma in NSCLC patients. Of note, we revealed the decreased stimulatory activity of plasma in patients who responded to chemotherapy.
Our findings demonstrated that the plasma of advanced NSCLC patients required TLR-stimulating nucleic acid immunoglobulin complexes and could discriminate the responsiveness to chemotherapy, which might provide a novel mechanism by which the proinflammatory immune response was induced and a potential new biomarker for evaluating responsiveness to chemotherapy in NSCLC patients.
- Non-small cell lung cancer
- Toll-like receptor
- Immune complex
Lung cancer is the leading cause of cancer-related death worldwide . Approximately 85% of lung cancers are non-small cell lung cancer (NSCLC), most of which are only diagnosed at advanced stages when therapeutic options are often restricted to systemic chemotherapy –. However, chemotherapeutic treatments for NSCLC are still relatively ineffective . A better understanding of the molecular and cellular processes during chemotherapy of advanced NSCLC patients was urgently needed.
Recent study revealed the presence of endogenous nucleic acid-immunoglobulin complexes in the plasma of cancer patients . It has been known for some time that endougenous nucleic acid-immunoglobulin complexes could induce the proinflammatory responses efficiently –. Accumulating data showed that the plasma proinflammatory cytokines were associated with the progression of NSCLC in patients ,–. These studies implicated a potential stimulatory effect of plasma in NSCLC patients. However, the stimulatory effect of plasma in advanced NSCLC patients and its correlation with their response to chemotherapy still remain unclear.
Here we reported that nucleic acid-immunoglobulin complexes in plasma from NSCLC patients could effectively induce proinflammatory cytokines through Toll like receptor (TLR) 8 and TLR9. We revealed a reduced stimulatory activity of plasma in patients who responded to chemotherapy. Our findings provided a novel mechanism by which the proinflammatory immune response was initiated and propagated and a promising new method for discriminating the response to chemotherapy in advanced NSCLC patients.
The NSCLC plasma could induce proinflammatory response
Nucleic acid and protein were required for the stimulatory activity of NSCLC plasma
TLR8 and TLR9 conferred the stimulatory activity of NSCLC plasma
The stimulatory activity of NSCLC plasma was decreased in patients who responded to chemotherapy
The discovery of a series of innate immune-specific receptors activated by pathogen associated molecular patterns led to a new understanding of innate immunity mechanisms ,. Among the innate immune-specific receptors, the best characterized are the Toll like receptors (TLRs), which are primary identified mainly on cells of the immune system, and play an essential role in adaptive immunity –. Recently, accumulating data suggested that TLRs were involved in the development of antitumor immunity –. In lung cancer patients, accumulating evidence suggested that TLR9 signaling played a crucial role in anti-tumor immunity –. However, TLR9 response to CpG oligonucleotide (ODN) in human lung cancer cells could also enhance their growth and invasive potential in vitro and in vivo –. Besides, TLR9 signaling could increase the release of VEGF in a mouse model of lung cancer . Therefore, the potential role of TLRs in tumor immunity was complex and still deserved to be elucidated. Our current study showed that NSCLC plasma could induce the proinflammatory cytokines. Of note, TLR8 and TLR9 signaling contributed to the generation of proinflammatory immune responses in advanced NSCLC patients. In addition, NSCLC plasma effectively induced expressions of pro-inflammatory cytokines from autologous NSCLC PBMCs (Additional file 1: Figure S1). Our findings were consistent with previous studies, which showed that the nucleic acid-immunoglobulin complexes were effect to induce immune response and thus played crucial roles in autoimmune disease and antitumor immunity ,, and provided a novel insight into the production of proinflammatory cytokines in NSCLC patients.
In present study, we revealed a reduced stimulatory activity of plasma in NSCLC patients who responded to chemotherapy. Our data were in line with previous evidence which showed that high levels and insufficient decreases of nucleosomes during the first cycle of chemotherapy indicated poor outcome of NSCLC patients , and the previous study which found that the circulating tumor cells and tumor DNA in peripheral blood was associated with clinical response to chemotherapy in NSCLC patients . Our results suggested that reduced chemotherapy resistance was associated with TLR-stimulating nucleic acid immunoglobulin complexes in peripheral blood of advanced NSCLC patients. However, the precise mechanisms by which the nucleic acid-immunoglobulin complexes were generated and involved in antitumor immunity undoubtedly need successive studies.
We should acknowledge some limitations of this study. The clinical sample size in this study was relatively small, and thus, large-scale studies were needed. The precise mechanisms by which the nucleic acid-immunoglobulin complexes were generated and involved in antitumor immunity undoubtedly needed successive studies. In addition, the findings should be tested at individual level to further the translational study.
Our results suggested that the stimulatory activity of plasma in the form of TLR-stimulating nucleic acid immunoglobulin complexes in patients with advanced NSCLC was associated with their chemotherapy resistance. These findings might provide a novel mechanism by which proinflammatory immune responses were initiated and propagated in NSCLC patients and a potential new method for discriminating the NSCLC patients who responded to chemotherapy.
This study was approved by the Ethics Committee of Tongji University. The collection and storage of patient medical information was analyzed anonymously. The peripheral blood samples were collected after obtaining written informed consent.
Characteristics of the advanced NSCLC patients
71 ± 76
Not classified carcinoma
Mode of therapy
Classification of response to chemotherapy
The classification of response to chemotherapy was performed as previously described . Before start of the third cycle of chemotherapy, staging investigations were done consisting of clinical examination, whole body computed tomography, and laboratory examinations. The response to therapy was classified according to the World Health Organization classifications defining “remission” as reduction of the tumor volume ≥50%, “progression” as increase of the tumor volume ≥25% or appearance of new tumor manifestations, and “no change” as reduction of the tumor volume <50% or increase <25%. In this study, 12 patients reached remission (42.9%), 11 suffered from progression (39.3%), and 5 had no change of disease (17.8%). The patients with “progression” and “no change” were joined to the group of nonresponders to therapy, whereas patients with remission were classified as responders to therapy.
Sample Collection and preparation
Whole-blood samples were collected before the first, second, and third cycle of chemotherapy for determination of their stimulatory effect of plasma. Plasma was isolated following centrifugation of whole blood. PBMCs were isolated from whole-blood specimens by Ficoll-Hypaque density gradient centrifugation (Sigma-Aldrich).
Detection of cytokines
qRT-PCR was used to detect a broad array of cytokines and chemokines, using gene specific sense and anti-sense primers, as previously described ,. In experiments using PBMCs, PBMCs (2 × 106/ml) were stimulated with conditioned medium containing 20% of NSCLC plasma (vol/vol). Specifically, 1 million cells in suspension were stimulated with either TLR agonist or 20% patient plasma for 6 hours prior to harvesting cells for RNA extraction. In experiments using TLR-expressing cell lines, cells were seeded at 2 × 105 cells/well, rested in RPMI 1640 overnight, and then exposed to either TLR agonists or 20% patient plasma for the indicated time. Exposure to 20% of a single lot of fetal bovine plasma was used as a negative control. Relative quantification of gene expression was normalized against the housekeeping gene GAPDH.
Isolation of ICs and treatment of plasma with nucleases and protease
Isolation of ICs and treatment of plasma with nucleases and protease were achieved as previously described . Immune complexes (ICs) were isolated from patient plasma using the IgG Purification Kit (Pierce) per the manufacturer’s instructions. To test the role of nucleic acids in the immunostimulatory activity of test plasma, 20 μl patient plasma were treated with 20 units of DNase I (Ambion) or 5 units of RNase (Promega) for 30 minutes at room temperature before stimulation of cells. Protease treatment of test plasma was achieved using 20 μl of immobilized papain (Pierce) for 4 h at room temperature prior to stimulation of cells.
TLR transfected HEK293 cells and TLR siRNA
HEK293 cells stably expressing human TLR3, TLR4, TLR8, TLR9, and control cells, the TLR agonist as well as the shRNA targeting human TLR3, TLR4, TLR8 and TLR9, were all purchased from Invivogen and used according to the instructions.
Data are presented as the mean ± standard deviation from three independent experiments performed in triplicate. T tests were used for statistical analyses using the program PRISM 6.0 (GraphPad Software Inc., San Diego, CA, USA). P < 0.05 was considered to be significant.
We thank Professor Qinchuan Li for useful comments and Dr. Yang Han for technical assistance. This work was supported by National Natural Science Foundation of China (81372347,81071744), Shanghai Committee of Science and Technology (11DZ1973801), Science and Technology Commission of Shanghai Pudong New Area (PKJ2009-Y05), Shanghai Pudong New Area Academic Leader in Health System (PWRd2010-01), and Basic Research Program supported by the Shanghai Committee of Science and Technology (11JC1410900).
- Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR: Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res. 2012, 18: 2391-2401. 10.1158/1078-0432.CCR-11-3148.View ArticlePubMedGoogle Scholar
- Holdenrieder S, von Pawel J, Dankelmann E, Duell T, Faderl B, Markus A, Siakavara M, Wagner H, Feldmann K, Hoffmann H, Raith H, Nagel D, Stieber P: Nucleosomes and CYFRA 21–1 indicate tumor response after one cycle of chemotherapy in recurrent non-small cell lung cancer. Lung Cancer. 2009, 63: 128-135. 10.1016/j.lungcan.2008.05.001.View ArticlePubMedGoogle Scholar
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 2007, 57: 43-66. 10.3322/canjclin.57.1.43.View ArticlePubMedGoogle Scholar
- Mountain CF: The international system for staging lung cancer. Semin Surg Oncol. 2000, 18: 106-115. 10.1002/(SICI)1098-2388(200003)18:2<106::AID-SSU4>3.0.CO;2-P.View ArticlePubMedGoogle Scholar
- Postel-Vinay S, Vanhecke E, Olaussen KA, Lord CJ, Ashworth A, Soria JC: The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Nat Rev Clin Oncol. 2012, 9: 144-155. 10.1038/nrclinonc.2012.3.View ArticlePubMedGoogle Scholar
- Lin Y, Zhang L, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea EP, Ritz J, Hacohen N, Means TK, Wu CJ: Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. J Clin Invest. 2011, 121: 1574-1584. 10.1172/JCI44581.View ArticlePubMed CentralPubMedGoogle Scholar
- Means TK, Latz E, Hayashi F, Murali MR, Golenbock DT, Luster AD: Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9. J Clin Invest. 2005, 115: 407-417. 10.1172/JCI23025.View ArticlePubMed CentralPubMedGoogle Scholar
- Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M: Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012, 13: 832-842. 10.1038/ni.2376.View ArticlePubMed CentralPubMedGoogle Scholar
- Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC: Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians. Cancer Epidemiol Biomarkers Prev. 2009, 18: 215-222. 10.1158/1055-9965.EPI-08-0705.View ArticlePubMed CentralPubMedGoogle Scholar
- Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res. 1996, 2: 553-559.PubMedGoogle Scholar
- Tas F, Duranyildiz D, Argon A, Oğuz H, Camlica H, Yasasever V, Topuz E: Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol. 2005, 22: 353-358. 10.1385/MO:22:4:353.View ArticlePubMedGoogle Scholar
- Songür N, Kuru B, Kalkan F, Ozdilekcan C, Cakmak H, Hizel N: Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori. 2004, 90: 196-200.PubMedGoogle Scholar
- Akira S, Uematsu S, Takeuchi O: Pathogen recognition and innate immunity. Cell. 2006, 124: 783-801. 10.1016/j.cell.2006.02.015.View ArticlePubMedGoogle Scholar
- Lee CC, Avalos AM, Ploegh HL: Accessory molecules for Toll-like receptors and their function. Nat Rev Immunol. 2012, 12: 168-179.PubMed CentralPubMedGoogle Scholar
- Kawai T, Akira S: The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010, 11: 373-384. 10.1038/ni.1863.View ArticlePubMedGoogle Scholar
- O'Neill LA, Golenbock D, Bowie AG: The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol. 2013, 13: 453-460.View ArticlePubMedGoogle Scholar
- Kawai T, Akira S: Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011, 34: 637-650. 10.1016/j.immuni.2011.05.006.View ArticlePubMedGoogle Scholar
- Kutikhin AG: Association of polymorphisms in TLR genes and in genes of the Toll-like receptor signaling pathway with cancer risk. Hum Immunol. 2011, 72: 1095-1116. 10.1016/j.humimm.2011.07.307.View ArticlePubMedGoogle Scholar
- Hamm S, Rath S, Michel S, Baumgartner R: Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists. J Immunotoxicol. 2009, 6: 257-265. 10.3109/15476910903286733.View ArticlePubMedGoogle Scholar
- Kaczanowska S, Joseph AM, Davila E: TLR agonists: our best frenemy in cancer immunotherapy. J Leukoc Biol. 2013, 93: 847-863. 10.1189/jlb.1012501.View ArticlePubMed CentralPubMedGoogle Scholar
- Pinto A, Morello S, Sorrentino R: Lung cancer and Toll-like receptors. Cancer Immunol Immunother. 2011, 60: 1211-1220. 10.1007/s00262-011-1057-8.View ArticlePubMedGoogle Scholar
- Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JS, Blasinska-Morawiec M, Serwatowski P, Krzakowski M, Jassem J, Tan EH, Benner RJ, Ingrosso A, Meech SJ, Readett D, Thatcher N: A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol. 2012, 23: 72-77. 10.1093/annonc/mdr030.View ArticlePubMedGoogle Scholar
- Yamada K, Nakao M, Fukuyama C, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Ohe Y, Ohki E, Hashimoto J, Tamura T: Phase I study of TLR9 agonist PF-3512676 in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer. Cancer Sci. 2010, 101: 188-195. 10.1111/j.1349-7006.2009.01361.x.View ArticlePubMedGoogle Scholar
- Ren T, Wen ZK, Liu ZM, Qian C, Liang YJ, Jin ML, Cai YY, Xu L: Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances anti-tumor responses of peripheral blood mononuclear cells from human lung cancer patients. Cancer Invest. 2008, 26: 448-455. 10.1080/07357900701681608.View ArticlePubMedGoogle Scholar
- Ren T, Wen ZK, Liu ZM, Liang YJ, Guo ZL, Xu L: Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis. Cancer Biol Ther. 2007, 6: 1704-1709. 10.4161/cbt.6.11.4826.View ArticlePubMedGoogle Scholar
- Xu L, Zhou Y, Liu Q, Luo JM, Qing M, Tang XY, Yao XS, Wang CH, Wen ZK: CXCR4/SDF-1 pathway is crucial for TLR9 agonist enhanced metastasis of human lung cancer cell. Biochem Biophys Res Commun. 2009, 382: 571-576. 10.1016/j.bbrc.2009.03.072.View ArticlePubMedGoogle Scholar
- Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, Zhou Y, Zhou H, Wen Z: TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 2009, 15: 623-630. 10.1007/s12253-009-9162-0.View ArticlePubMedGoogle Scholar
- Xu L, Wang C, Wen Z, Yao X, Liu Z, Li Q, Wu Z, Xu Z, Liang Y, Ren T: Selective up-regulation of CDK2 is critical for TLR9 signaling stimulated proliferation of human lung cancer cell. Immunol Lett. 2010, 127: 93-99. 10.1016/j.imlet.2009.10.002.View ArticlePubMedGoogle Scholar
- Wang C, Fei G, Liu Z, Li Q, Xu Z, Ren T: HMGB1 was a pivotal synergistic effecor for CpG oligonucleotide to enhance the progression of human lung cancer cells. Cancer Biol Ther. 2012, 13: 727-736. 10.4161/cbt.20555.View ArticlePubMedGoogle Scholar
- Li Q, Li X, Guo Z, Xu F, Xia J, Liu Z, Ren T: MicroRNA-574-5p was pivotal for TLR9 signaling enhanced tumor progression via down-regulating checkpoint suppressor 1 in human lung cancer. PLoS One. 2012, 7: e48278-10.1371/journal.pone.0048278.View ArticlePubMed CentralPubMedGoogle Scholar
- Xu L, Wen Z, Zhou Y, Liu Z, Li Q, Fei G, Luo J, Ren T: MicroRNA-7-regulated TLR9 signaling-enhanced growth and metastatic potential of human lung cancer cells by altering the phosphoinositide-3-kinase, regulatory subunit 3/Akt pathway. Mol Biol Cell. 2013, 24: 42-55. 10.1091/mbc.E12-07-0519.View ArticlePubMed CentralPubMedGoogle Scholar
- Sorrentino R, Morello S, Giordano MG, Arra C, Maiolino P, Adcock IM, Pinto A: CpG-ODN increases the release of VEGF in a mouse model of lung carcinoma. Int J Cancer. 2011, 128: 2815-2822. 10.1002/ijc.25626.View ArticlePubMedGoogle Scholar
- Holdenrieder S, Stieber P, von Pawel J, Raith H, Nagel D, Feldmann K, Seidel D: Circulating nucleosomes predict the response to chemotherapy in patients with advanced non-small cell lung cancer. Clin Cancer Res. 2004, 10: 5981-5987. 10.1158/1078-0432.CCR-04-0625.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.